Compare CNVS & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNVS | TVGN |
|---|---|---|
| Founded | 2000 | 2020 |
| Country | United States | United States |
| Employees | 218 | N/A |
| Industry | Consumer Electronics/Video Chains | Blank Checks |
| Sector | Consumer Discretionary | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6M | 63.9M |
| IPO Year | 2016 | N/A |
| Metric | CNVS | TVGN |
|---|---|---|
| Price | $2.64 | $7.49 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 146.2K | 17.3K |
| Earning Date | 02-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.99 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $78,181,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $84.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 59.13 | N/A |
| 52 Week Low | $1.77 | $0.14 |
| 52 Week High | $7.39 | $10.76 |
| Indicator | CNVS | TVGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.57 | 60.32 |
| Support Level | $2.31 | $0.47 |
| Resistance Level | $3.47 | $9.40 |
| Average True Range (ATR) | 0.15 | 0.80 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 79.57 | 36.33 |
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.